Cargando…
Death due to COVID‐19 in a patient with diabetes, epilepsy, and gout comorbidities
There is evidence of increased incidence, rapid progression, and poor prognosis of COVID‐19 in patients with underlying comorbidities such as diabetes and epilepsy. Developing effective treatment regimens for COVID‐19 patients with multiple comorbidities is crucial, as patients' past medical hi...
Autores principales: | Safdarian, Amir Reza, Momenzadeh, Kaveh, Kahe, Farima, Farhangnia, Pooya, Rezaei, Nima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753325/ https://www.ncbi.nlm.nih.gov/pubmed/33362925 http://dx.doi.org/10.1002/ccr3.3557 |
Ejemplares similares
-
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
por: Farhangnia, Pooya, et al.
Publicado: (2022) -
COVID-19: A double threat to takotsubo cardiomyopathy and spontaneous coronary artery dissection?
por: Shojaei, Fahimehalsadat, et al.
Publicado: (2021) -
Case Report: Death due to COVID-19 in Three Brothers
por: Yousefzadegan, Sedigheh, et al.
Publicado: (2020) -
Gout and comorbidity: a nominal group study of people with gout
por: Singh, Jasvinder A.
Publicado: (2017) -
Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy
por: Aghamajidi, Azin, et al.
Publicado: (2022)